Alpha Paradigm Partners’s Vivos Therapeutics VVOS Stock Holding History

Alpha Paradigm Partners’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-397	Closed	-$66K	–	678
2021 Q1	$66K	Buy	+397	New	+$70.9K	0.03%	413

Other funds holding VVOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Alpha Paradigm Partners's VVOS Position: Q2 2021 in Review

Alpha Paradigm Partners sold out of Vivos Therapeutics (VVOS) in Q2 2021, closing a stake of 397 shares — an estimated $66K sold.

Alpha Paradigm Partners first reported a position in VVOS in Q1 2021 and held it in 1 quarter. The position peaked at $66K in Q1 2021. 29 funds tracked by Wall St. Rank hold VVOS as of Q2 2021.

Alpha Paradigm Partners reported no remaining Vivos Therapeutics position as of Q2 2021 after selling out during the quarter.
Alpha Paradigm Partners sold 397 Vivos Therapeutics shares in Q2 2021, an estimated $66K.
Alpha Paradigm Partners first reported a position in Vivos Therapeutics in Q1 2021 and held it in 1 quarter.
Alpha Paradigm Partners's Vivos Therapeutics position peaked at $66K in Q1 2021.
29 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2021.

Based on Alpha Paradigm Partners's 13F filing for Q2 2021, filed 13 Aug 2021.